SWATH-proteomics of ibrutinib’s action in myeloid leukemia initiating mutated G-CSFR signaling

PURPOSE: To evaluate cellular protein changes in response to treatment with an approved drug, ibrutinib, in cells expressing normal or mutated Granulocyte-Colony Stimulating Factor Receptor (G-CSFR). G-CSFR mutations are associated with some hematological malignancies. Previous studies showed the ef...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Proteomics Clin Appl
Asıl Yazarlar: Dwivedi, Pankaj, Chutipongtanate, Somchai, Muench, David E., Azam, Mohammad, Grimes, H. Leighton, Greis, Kenneth D.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7492401/
https://ncbi.nlm.nih.gov/pubmed/32319217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prca.201900144
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller